Lipocine Inc. – NASDAQ:LPCN
Lipocine stock price today
$2.88
-1.88
-39.5%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Lipocine stock price monthly change
-38.10%
month
Lipocine stock price quarterly change
-38.10%
quarter
Lipocine stock price yearly change
+61.36%
year
Lipocine key metrics
Market Cap | 25.93M |
Enterprise value | N/A |
P/E | -2.41 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | 55.37 |
Price/Book | 0.77 |
PEG ratio | N/A |
EPS | -1.71 |
Revenue | N/A |
EBITDA | -9.80M |
Income | -8.96M |
Revenue Q/Q | 13751.92% |
Revenue Y/Y | -54.73% |
Profit margin | -2151.73% |
Oper. margin | -2423.87% |
Gross margin | -1233.79% |
EBIT margin | -2423.87% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeLipocine stock price history
Lipocine stock forecast
Lipocine financial statements
| Jun 2023 | 0 | -3.54M | |
|---|---|---|---|
| Sep 2023 | -3.12M | -6.65M | 213.04% |
| Dec 2023 | 54.99K | -2.28M | -4149.78% |
| Mar 2024 | 7.61M | 3.51M | 46.13% |
| Dec 2023 | 54.99K | -2.28M | -4149.78% |
|---|---|---|---|
| Mar 2024 | 7.61M | 3.51M | 46.13% |
| Oct 2025 | 4.38M | 53.15K | 1.21% |
| Dec 2025 | 7.11M | 1.22M | 17.19% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 30483460 | 1.93M | 6.34% |
|---|---|---|---|
| Sep 2023 | 24752343 | 2.27M | 9.17% |
| Dec 2023 | 23001072 | 2.63M | 11.44% |
| Mar 2024 | 25446555 | 1.49M | 5.86% |
| Jun 2023 | -3.30M | 3.56M | -5.2K |
|---|---|---|---|
| Sep 2023 | -2.60M | 1.24M | 421.08K |
| Dec 2023 | -2.02M | 2.72M | -5.29K |
| Mar 2024 | 2.40M | -4.08M | -8.1K |
Lipocine alternative data
| Aug 2023 | 17 |
|---|---|
| Sep 2023 | 15 |
| Oct 2023 | 15 |
| Nov 2023 | 15 |
| Dec 2023 | 17 |
| Jan 2024 | 17 |
| Feb 2024 | 17 |
| Mar 2024 | 17 |
| Apr 2024 | 17 |
| May 2024 | 17 |
| Jun 2024 | 17 |
| Jul 2024 | 17 |
Lipocine other data
3.65%
-8.18%
of LPCN is owned by hedge funds
25
-22
3.24M
-7.25M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Sep 2022 | 100000 | 0 |
| Nov 2022 | 96739 | 0 |
| Mar 2023 | 204000 | 0 |
| May 2023 | 8706 | 0 |
| Patent |
|---|
Grant Filling date: 14 May 2019 Issue date: 6 Sep 2022 |
Grant Filling date: 20 Nov 2020 Issue date: 28 Jun 2022 |
Grant Filling date: 30 Jul 2020 Issue date: 21 Jun 2022 |
Grant Filling date: 8 Apr 2020 Issue date: 21 Jun 2022 |
Grant Filling date: 7 May 2021 Issue date: 24 May 2022 |
Grant Filling date: 8 Apr 2020 Issue date: 26 Apr 2022 |
Grant Filling date: 15 Apr 2020 Issue date: 12 Apr 2022 |
Application Filling date: 15 May 2020 Issue date: 25 Nov 2021 |
Grant Utility: Steroidal compositions Filling date: 16 Oct 2020 Issue date: 6 Jul 2021 |
Application Filling date: 24 Feb 2021 Issue date: 17 Jun 2021 |
-
What's the price of Lipocine stock today?
One share of Lipocine stock can currently be purchased for approximately $2.88.
-
When is Lipocine's next earnings date?
Unfortunately, Lipocine's (LPCN) next earnings date is currently unknown.
-
Does Lipocine pay dividends?
No, Lipocine does not pay dividends.
-
How much money does Lipocine make?
Lipocine has a market capitalization of 25.93M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 670.16% to -2.85M US dollars.
-
What is Lipocine's stock symbol?
Lipocine Inc. is traded on the NASDAQ under the ticker symbol "LPCN".
-
What is Lipocine's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Lipocine?
Shares of Lipocine can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Lipocine have?
As Jul 2024, Lipocine employs 17 workers.
-
When Lipocine went public?
Lipocine Inc. is publicly traded company for more then 11 years since IPO on 22 Oct 2013.
-
What is Lipocine's official website?
The official website for Lipocine is lipocine.com.
-
Where are Lipocine's headquarters?
Lipocine is headquartered at 675 Arapeen Drive, Salt Lake City, UT.
-
How can i contact Lipocine?
Lipocine's mailing address is 675 Arapeen Drive, Salt Lake City, UT and company can be reached via phone at 801 994 7383.
Lipocine company profile:
Lipocine Inc.
lipocine.comExchange:
NASDAQ
Full time employees:
17
Industry:
Biotechnology
Sector:
Healthcare
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.
675 Arapeen Drive
Salt Lake City, UT 84108
Salt Lake City, UT 84108
CIK: 0001535955
ISIN: US53630X2036
CUSIP: 53630X104
